Phase II angiogenesis stimulators

Domenico Ribatti, Silvia Baiguera

Research output: Contribution to journalArticlepeer-review


Introduction: Therapeutic angiogenesis is a strategy of inducing new collateral vessels and stimulating new capillaries that enhance tissue oxygen exchange in ischemic cardiovascular disorders, including acute myocardial infarction, chronic cardiac ischemia, peripheral artery disease and stroke. Areas covered: Over the last 10 years, promising results of early clinical trials have generated great expectation on the potential of therapeutic angiogenesis. However, even if large randomized placebo-controlled and double-blinded Phase II clinical trials have confirmed the feasibility, safety and potential effectiveness of therapeutic angiogenesis, they provided very limited evidence of its efficacy in terms of clinical benefit. Expert opinion: Results of the latest trials on therapeutic angiogenesis have not provided satisfactory results. Much is still unknown about the optimal delivery of angiogenic factors. Trials using alternative growth factors, dose regimens and methods of delivery are needed to enhance the treatment benefit of therapeutic angiogenesis.

Original languageEnglish
Pages (from-to)1157-1166
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number9
Publication statusPublished - Sep 2013


  • Angiogenesis
  • Gene transfer
  • Therapeutic angiogenesis
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II angiogenesis stimulators'. Together they form a unique fingerprint.

Cite this